Nkarta, Inc. (NASDAQ:NKTX) CEO Paul J. Hastings Sells 17,378 Shares

Nkarta, Inc. (NASDAQ:NKTX) CEO Paul J. Hastings sold 17,378 shares of the company’s stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $2.20, for a total value of $38,231.60. Following the completion of the sale, the chief executive officer now owns 319,859 shares of the company’s stock, valued at $703,689.80. This represents a 5.15 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Nkarta Stock Performance

Shares of NKTX opened at $2.47 on Friday. The company has a 50 day moving average of $2.54 and a two-hundred day moving average of $4.21. Nkarta, Inc. has a twelve month low of $2.08 and a twelve month high of $16.24.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on NKTX. HC Wainwright lowered their price objective on shares of Nkarta from $22.00 to $18.00 and set a “buy” rating for the company in a research note on Monday, November 11th. Mizuho lowered their price target on shares of Nkarta from $20.00 to $16.00 and set an “outperform” rating for the company in a research report on Thursday, November 21st. Needham & Company LLC reduced their price objective on shares of Nkarta from $13.00 to $11.00 and set a “buy” rating for the company in a research note on Friday, November 8th. Rodman & Renshaw started coverage on Nkarta in a research report on Wednesday, October 9th. They set a “buy” rating and a $14.00 target price on the stock. Finally, RODMAN&RENSHAW raised Nkarta to a “strong-buy” rating in a research report on Wednesday, October 9th. Five equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $15.00.

Institutional Trading of Nkarta

Several hedge funds and other institutional investors have recently made changes to their positions in the business. AQR Capital Management LLC acquired a new position in Nkarta during the 2nd quarter valued at about $938,000. Federated Hermes Inc. grew its stake in shares of Nkarta by 28,478.7% during the second quarter. Federated Hermes Inc. now owns 135,749 shares of the company’s stock worth $802,000 after acquiring an additional 135,274 shares during the last quarter. Wasatch Advisors LP increased its holdings in shares of Nkarta by 31.7% during the third quarter. Wasatch Advisors LP now owns 1,834,680 shares of the company’s stock valued at $8,293,000 after acquiring an additional 442,125 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Nkarta by 3.0% in the 3rd quarter. Geode Capital Management LLC now owns 1,171,026 shares of the company’s stock valued at $5,294,000 after purchasing an additional 33,927 shares during the last quarter. Finally, Cubist Systematic Strategies LLC acquired a new stake in Nkarta in the 2nd quarter worth approximately $1,489,000. Hedge funds and other institutional investors own 80.54% of the company’s stock.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.